The specter of generic rivalry has repeatedly loomed around copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the prospects of related pharmaceutical portfolios. While initial times saw significant gains, the exclusivity end has opened the way for discounted copies, possibly reducing earnings and presenting a genuine hazard for